Arkolith/Insider Trading/LEXX/Form 4/A

Bunka Christopher

Chief Executive Officer, DirectorLexaria Bioscience Corp. (LEXX) · full profile →Form 4/A · filed Oct 18, 2022
Net Buying
Open-Market Buys
$78K
Open-Market Sells
$0
Net Open-Market Flow
$78K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 13, 2022Buy(P)17K$2.10$35K254K
Oct 12, 2022Buy(P)22K$1.99$44K238K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001855763-22-000019) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML

Keep exploring

Connected pages for Lexaria Bioscience Corp.

Build

Ask your agent about LEXX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001855763-22-000019"
Ask your agent
Use Arkolith to summarize insider buying and selling at Lexaria Bioscience Corp.
over the last 90 days and cite the filings.